Entrectinib (Rozlytrek®) accepted for use within NHS Scotland for treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)

Approved for patients not previously treated with ROS1 inhibitors; based on a phase II study in patients with ROS1-positive advanced NSCLC, in which the objective response rate was 72%.

Source:

Scottish Medicines Consortium